Cytorex Biosciences Inc, (Cytorex), a South Florida-based biotechnology company with research and development facilities in Texas, announced today that the results of an Acute Toxicology and Lethal Dose 50 (LD-50) study conducted on Cytoreg® ionic therapeutic technology in an In Vivo Model under the BioULA agreement of the University of Merida - ULA- in Venezuela and its subsidiary Cytorex de Venezuela S. A, has been published in The Latin American Journal of Development (LAJD) ISSN: 2674-9297.
https://latinamericanpublicacoes.com.br/ojs/index.php/jdev/article/view/314/295

It is important to highlight that the LD50 is a way of measuring the potential short-term poisoning (acute toxicity) that can be caused by an amount of ionic therapy, which, used only once, causes the death of 50% (one half) of a group in the In Vivo test model. The results obtained are expressed in milligrams of Cytoreg® per kilogram of animal body weight used in the in vivo model.

Cytoreg® ionic therapy is in liquid form, and contains a variety of ions provided by acids, whose conjugated bases have different electrical charges. It constitutes an ion transport complex of positively charged cations and negatively charged anions in high concentrations that help regulate mitochondrial and cellular metabolism. It utilizes the inorganic fluoride ion (HF) as the main active compound. Therefore, all the concentrations described in the results of the research work published in The Latin American Journal of Development (LAJD) ISSN: 2674-9297, are referred to hydrofluoric acid (HF), as it is the active compound of the formulation. Conventional pharmacological methods were used, and it was found that the average lethal dose in the In Vivo Model of rats was 44.83 mg/kg and 0.82 ml/kg. At the minimum dose concentration of 0.49 mL/kg body weight.

"The results obtained have revealed, that our ionic therapy has a low toxicity, and its use can be daily and at high concentrations. This undoubtedly offers a very favorable advantage for the treatment of cancer, autoimmune, neurodegenerative, and other pathologies. Therefore, as toxicology is nowadays considered an essential tool for the development of new drugs, Cytorex Biosciences Inc. has included in its Research and Development Plan for its novel ionic therapeutic technology, the performance of studies of several aspects that rule out the possible toxic action. Our studies range from the evaluation of the absorption, distribution, biotransformation and excretion of our therapeutic agent and its ions (toxicokinetic) to the interactions on targets or toxicological targets (toxicodynamic), which can lead to adaptive responses, tolerance, repair and partial or total damage... Our goal is to perform all the necessary tests in this area, which will allow us to demonstrate safety and non-toxicity in its use", said William Jimenez, Chairman of the company's Board of Directors.

About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is a small innovative biotechnology company based in South Florida with a research and development coordination center in Kingwood, Texas focused on the development and research of ionic therapeutic agents, based on Cytoreg® ionic therapeutic technology, for the development of targeted therapeutic agents for the treatment of pathologies such as cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, bacterial-derived pathologies, viruses such as Ebola and SARS-CoV-2 among other pathologies. Cytorex has worldwide intellectual property rights on its technologies, with other new patents pending and others in development. Cytorex Biosciences Inc. is currently in the final stage of the preclinical phase for PRE-IND review by USFDA of its ionic therapeutic agent designed for the treatment of Glioblastoma Multiforme brain tumors.